NASDAQ:ACIU AC Immune Q3 2025 Earnings Report $2.63 -0.05 (-1.87%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$2.64 +0.00 (+0.19%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast AC Immune EPS ResultsActual EPS-$0.20Consensus EPS -$0.22Beat/MissBeat by +$0.02One Year Ago EPSN/AAC Immune Revenue ResultsActual Revenue$1.18 millionExpected Revenue$0.81 millionBeat/MissBeat by +$373.05 thousandYoY Revenue GrowthN/AAC Immune Announcement DetailsQuarterQ3 2025Date11/4/2025TimeBefore Market OpensConference Call DateTuesday, November 4, 2025Conference Call Time1:00PM ETUpcoming EarningsAC Immune's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(6-K) AC Immune Earnings HeadlinesAC Immune Calls October EGM to Add Veteran Biopharma Financier Tom Graney to BoardSeptember 3, 2026 | tipranks.comAC Immune’s New Phase 1 NLRP3 Trial Puts Inflammation Strategy in FocusSeptember 2, 2026 | tipranks.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 19 at 1:00 AM | Stansberry Research (Ad)Analysts Offer Insights on Healthcare Companies: AC Immune SA (ACIU) and Gilead Sciences (GILD)August 22, 2026 | theglobeandmail.comAC Immune shares rise after encouraging early phase 1 data for ACI-19764August 20, 2026 | msn.comAC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for PipelineAugust 20, 2026 | benzinga.comSee More AC Immune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email. Email Address About AC ImmuneAC Immune (NASDAQ:ACIU) SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins. AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them. Its pipeline has included vaccine and antibody-based approaches aimed at amyloid-beta and tau, as well as programs addressing other proteins linked to neurodegeneration. The company has also pursued collaborations with larger pharmaceutical companies to advance selected candidates. AC Immune serves the global biopharmaceutical and healthcare markets through research and development conducted primarily in Switzerland and through international partnerships and clinical studies. Andrea Pfeifer has served as the company’s chief executive officer and has been associated with its leadership since its early development.View AC Immune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
